The FDA approves Pfizer’s oral COVID-19 drug; hundreds of thousands of people lose Medicaid coverage after pandemic protections expire; irregular menstrual cycles seem to be linked with higher cardiovascular disease (CVD) risks.
The FDA Thursday granted full approval to Pfizer’s COVID-19 oral antiviral pill, nirmatrelvir/ritonavir (Paxlovid), for use by adults at high risk for progression to acute disease, reported The Hill. The approval comes almost a year and a half after the drug earned an emergency use authorization and as deaths and hospitalizations from the virus continue to decrease. The drug has been shown to be most effective for patients who have not received a COVID-19 vaccine and those not previously infected.
Hundreds of thousands of low-income Americans have lost Medicaid coverage recently as part of an expansive unwinding of a pandemic-era policy that forbid states from removing people from the programs, according to The New York Times. Preliminary data show that many individuals lost coverage for procedural reasons, like when Medicaid recipients did not return paperwork to verify their eligibility or could not be located. The large number of terminations due to procedure suggests that people who are still qualified are losing coverage, including children. The coronavirus relief package guaranteeing continuous Medicaid coverage expired at the end of March.
Women with irregular menstrual cycles or cycle lengths may encounter a higher risk of cardiovascular disease (CVD), according to a new study, reported CNN Health. Cycles that are shorter than normal (<21 days) or longer than normal (>35 days) were associated with a higher risk of CVD and atrial fibrillation, according to the study published Wednesday. The researchers found that 2.5% of the women with regular cycles developed CVD, compared with 3.4% who had irregular cycles.
FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade
April 18th 2025Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.
Read More
Addressing the Demand for Mental Health Services During the COVID-19 Pandemic
May 25th 2021On this episode of Managed Care Cast, we speak with Gregory Harris, MD, MPH, DFAPA, senior medical director for behavioral health at Blue Cross Blue Shield of Massachusetts, about the challenges of meeting the demand for mental health service during the COVID-19 pandemic.
Listen
Bias Reduction, Better Access Key to COVID-19 Equity Gains
April 14th 2025Interventions that target enhancing health care equity among communities disproportionately affected by the COVID-19 pandemic can be improved by including comprehensive needs assessments at the patient, provider, and health system levels.
Read More